Abstract:Background: Immune checkpoint blockers (ICBs) are revolutionized therapeutic strategies for cancer, but most patients with solid neoplasms remain resistant to ICBs, partly because of the difficulty in reversing the highly immunosuppressive tumor microenvironment (TME). Exploring the strategies for tumor immunotherapy is highly dependent on the discovery of molecular mechanisms of tumor immune escape and potential therapeutic target. Krüppel-like Factor 5 (KLF5) is a cell-intrinsic oncogene to promote tumorigenesis. However, the cell-extrinsic effects of KLF5 on suppressing the immune response to cancer remain unclear. Methods: We analyzed the immunosuppressive role of KLF5 in mice models transplanted with KLF5-deleted/overexpressing tumor cells. We performed RNA sequencing, immunohistochemistry, western blotting, real time-PCR, ELISA, luciferase assay, chromatin immunoprecipitation (ChIP), and flow cytometry to demonstrate the effects of KLF5 on CD8+ T cell infiltration and related molecular mechanism. Single-cell RNA sequencing and spatial transcriptomics analysis were applied to further decipher the association between KLF5 expression and infiltrating immune cells. The efficacy of KLF5/COX2 inhibitors combined with anti-programmed cell death protein 1 (anti-PD1) therapy were explored in pre-clinical models. Finally, a gene-expression signature depending on KLF5/COX2 axis and associated immune markers was created to predict patient survival. Results: KLF5 inactivation decelerated basal-like breast tumor growth in a CD8+ T-cell-dependent manner. Transcriptomic profiling revealed that KLF5 loss in tumors increases the number and activated function of T lymphocytes. Mechanistically, KLF5 binds to the promoter of the COX2 gene and promotes COX2 transcription; subsequently, KLF5 deficiency decreases prostaglandin E2 (PGE2) release from tumor cells by reducing COX2 expression. Inhibition of the KLF5/COX2 axis increases the number and functionality of intratumoral antitumor T cells to synergize the antitumorigenic effects of anti-PD1 therapy. Analysis of patient datasets at single-cell and spatial resolution shows that low expression of KLF5 is associated with an immune-supportive TME. Finally, we generate a KLF5/COX2-associated immune score (KC-IS) to predict patient survival. Conclusions: Our results identified a novel mechanism responsible for KLF5-mediated immunosuppression in TME, and targeting the KLF5/COX2/PGE2 axis is a critical immunotherapy sensitizer.

Targeting the KLF5-EphA2 axis can restrain cancer stemness and overcome chemoresistance in basal-like breast cancer

Abstract A46: KLF4 Overcomes Tamoxifen Resistance by Suppressing MAPK Signaling Pathway in Breast Cancer

KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer

Eph receptor B6 shapes a cold immune microenvironment, inhibiting anti-cancer immunity and immunotherapy response in bladder cancer.

EphA2 promotes the transcription of KLF4 to facilitate stemness in oral squamous cell carcinoma

Transcription factor E2F8 is a therapeutic target in the basal-like subtype of breast cancer

A feedforward circuit between KLF5 and lncRNA KPRT4 contributes to basal-like breast cancer

WNT5B governs the phenotype of basal-like breast cancer by activating WNT signaling

Elevation of Receptor Tyrosine Kinase Epha2 Mediates Resistance to Trastuzumab Therapy

Inhibitory Effect of the Novel Tyrosine Kinase Inhibitor DCC-2036 on Triple-Negative Breast Cancer Stem Cells Through AXL-KLF5 Positive Feedback Loop

KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8 + T-cell-dependent antitumor immunity

Inhibition Of Super Enhancer Downregulates The Expression Of Klf5 In Basal-Like Breast Cancers

Mechanism of transcription factor KLF5 mediating acquired drug resistance in breast cancer cells

Regulation of KLF4 by Posttranslational Modification Circuitry in Endocrine Resistance.

FOXC1 is a Critical Mediator of EGFR Function in Human Basal-like Breast Cancer

Foxc1 Regulates Cancer Stem Cells Properties Via Inducing Smo-Independent Gli Activation And Confers Anti-Hedgehog Drug Resistance In Basal-Like Breast Cancer

Ligand‐independent EphA2 contributes to chemoresistance in small‐cell lung cancer by enhancing PRMT1‐mediated SOX2 methylation

Network Analysis Identifies Regulators of Basal-Like Breast Cancer Reprogramming and Endocrine Therapy Vulnerability

KLF15 Suppresses Tumor Growth and Metastasis in Triple-Negative Breast Cancer by Downregulating CCL2 and CCL7.

Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness

Abstract B02: Ephrin Receptor A10 Promotes PD-L1 Expression for Breast Cancer Immune Evasion